Alcon (NYSE: ALC) shares registered just barely in the plus column Tuesday. The company, purporting to be the global leader in eye care dedicated to helping people see brilliantly, announced results from time and motion studies demonstrating superior efficiency* with UNITY® Vitreoretinal Cataract System (VCS) for vitreoretinal and cataract surgery compared to CONSTELLATION® Vision Systemand CENTURION® Vision System with ACTIVE SENTRY ®.1-6
The studies were presented during the 25th Euretina Congress (Paris; 4-7 September), The Retina Society’s 58th Annual Scientific Meeting (Chicago; 10-13 September) and the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS; Copenhagen; 12-15 September).
"We invest heavily in surgical innovation because it's our responsibility as the global leader in eye care to elevate the market and provide Eye Care Professionals with the tools they need the most,” said Sean Clark, Vice President and General Manager, Global Surgical Franchise at Alcon. “We listened to the current needs of surgeons, who are looking for solutions to help drive efficiencies. We are proud to demonstrate that UNITY VCS helps do just that with this real-world evidence over our leading CONSTELLATION Vision System and CENTURION Vision System with ACTIVE SENTRY.”
ALC shares opened Tuesday up 13 cents to $77.54.
